Article sent to us by a GeoUser. First China (OTCCB:FCPG) shares are pulling back sharply today after a sharp run from around $1.00. Shares are down sharply to $3.20 in early trading today after soaring yesterday.
Source: http://www2.smallcapfortunes.com/firstchina/index.html
Dear Fellow Investor:
The bidding war could be just weeks away. But it gives us a “window” to buy First China Pharmaceutical Group (FCPG on the OTCBB) at the incredible price of just $1 to $1.50 per share.
As America’s #1 buyout target, FCPG shareholders could easily score 2,800% profit, turning a modest $3,000 investment into $84,000, or a $36,000 investment into $1 million.
This isn’t “pie in the sky.” But more accurately, it's a virtual foregone conclusion!
First China Pharmaceutical Group has been flying under the radar. And very few people know the unique set of circumstances surrounding its “impenetrable market position” that practically guarantees fortune-making profits!
But here’s the advance information you need...
The fastest growing
drug market in the world
is consolidating
under unprecedented
healthcare reform!
Advertisement, see disclaimer on bottom
American FCPG can be among the biggest winners in this massive transformation! Here’s why..
China is where the action is today. Even during the Great Global Recession, its white-hot 12% annual growth rate dropped to just “a sizzling 9%” rate (6 times better than the current U.S. rate).
Now, First China Pharma Group is about to become one of the biggest winners in an $850 billion transformation of China’s massive and severely antiquated drug distribution system, the purpose of which is to create..
A modern $80 billion drug market by 2013!
China’s National Development and Reform Commission (NDRC) is responsible for consolidating China’s major industries. First, they did the auto and auto-parts industries. Next, they did the cement industry. And now they’re doing drug distribution (with more to follow).
But here’s what’s important to FCPG shareholders who get their shares at today’s bargain prices...
China’s “drug distribution consolidation plan” is one of the most important aspects of the massive $850 billion healthcare overhaul by 2013, providing government-healthcare to every Chinese citizen, even in rural areas!
It’s the biggest government healthcare overhaul in the world, and a key part of an even bigger plan to make China the world’s #1 economic power by 2025!
If you haven’t already heard, China is ending it’s one-baby-per-couple law, beginning in 2011, with a total phase-out by the end of 2013. Which means the population will swell by tens of millions, and all these people will be using medications and OTC remedies.
FCPG is already a successful $21 million drug distributor in Yunnan, China’s fastest-growing province with a population of 46 million people!
Currently, FCPG has a 5,000 item product line (just small enough to let us buy shares today for $1 to $1.50). But very quickly FCPG will become one of the biggest companies under consolidation...
As it expands to other provinces and grows the pharmaceutical line to 30,000 products, while at the same time doubling its profit margins, as it gobbles up weaker competitors who will be forced out of business!
How can such a dramatic thing happen in such a short time? Because...
FCPG has been “chosen” by the Chinese Government to be one of just 14 companies licensed to sell drugs over the Internet.
Within a year, FCPG could be a $300 million company as it rapidly gobbles up weaker competitors who won’t be able to compete on price, quality, delivery, service, or anything else!
But even before FCPG reaches a $300 million market value, it’ll likely be bought out for $600 million. Why? For one, FCPG’s profits could double. But also...
Because buying FCPG represents possibly the only way for one of the “Big Four US Drug Distributors” to get into the fast-growing Chinese pharmaceutical market, now the 3rd largest in the world, and fast on its way to #1.
MOST IMPORTANT to us — At a $600 million value, FCPG shares will be worth about 28 times today’s share price. And that’s when...
Your $3,000 investment rockets to $84,000. Or your $36,000 investment vaults to $1 million!
Would you like a payday like that? Who wouldn’t! It’s the...
The profit opportunity
of the decade!
Hi, I’m Eric Dickson of Breakaway Stocks. I’ve done a ton of research on this Nevada-based company that has “privileged relationships” in China...
And after witnessing the number of multi-millionaires created in the Chinese auto and cement industry consolidations, I was anxious to find a hot play in “drug distribution” that would do the same for my readers.
FCPG is it! And that’s why I say call your broker or go online to your trading account right now!
FCPG is the only American company licensed and ordained by the Chinese Government to sell drugs over the Internet in China – a key part of the consolidation plan that will eliminate thousands of middlemen who now won’t be able to compete. More on this just head, but first...
Let me give you just one example of the kind of profits investors on the inside track can make on Chinese industry consolidation...
Advertisement, see disclaimer on bottom
You could score $$$ like
Goldman Sachs
Recently, Goldman Sachs put up $80 million for a small interest in Hongshi Cement Co in Zhejiang. Why cement? And why Hongshi?
Because China’s NRDC had “anointed Hongshi” as one of the 10 biggest winners under cement-industry consolidation (in the same way FCPG has just been anointed in drug distribution).
And there was a very good reason for this.
China is the world’s #1 cement market, and it previously had 5,000 cement producers, but the top 10 Chinese cement makers controlled only 20% of the market.
The NDRC believed that was way too fragmented, way too inefficient, and way out of line with China’s plans to become the #1 economic superpower in the world.
So, they forced consolidation, anointing ten big winners and weeding out thousands of weaker players, so that the top producers would then control 80% of the market.
Rigged? Yes. Fair to the losers? No. But...
The benefit to the country as a whole was lower prices, higher quality cement, speedier delivery, and faster industrial growth, which of course lifts the fast-rising middle class (who will of course be using drugs sold by FCPG).
In any case, who cares if “consolidation” is a rigged game, if we’re on the winning end of the fix. Goldman Sachs sure didn’t.
They sneaked in and grabbed a piece of one of the “anointed” cement producers. And already they’ve made 5 times their money, and will likely score 50 times their investment once consolidation is complete.
And the good news is that we can make the same kind of deal Goldman made, simply by picking up shares of FCPG today.
The Chinese government has given FCPG its “seal of approval” by granting it one of just 14 Internet drug sales licenses. In effect, its saying to FCPG – We want you to be one of the biggest drug distributors in China.
That’s why I say call your broker, or log-on to your investment account, and pick up FCPG right now, while shares are still just $1 to $1.50!
Let me tell you more about the consolidation process, and specifically the “competition-slaying advantage” of the Internet sales licensing scheme (the main reason we can make 2,800% profit).
Just 14 Internet Sales Licenses for all
of China’s 1.5 billion people!
China’s archaic system currently has 6,000 drug distributors, but after the consolidation and modernization plan is fully implemented, just 30 or 40 companies will remain...
And, specifically, just 14 of them will be the biggest winners because they’ll be the only ones with the Internet sales licenses.
As you know, modern business today is conducted over the Internet with very sophisticated sales and customer-service software. Think of what IBM, Oracle and SAP do for their clients.
No outmoded or lesser systems can compete on price, convenience, speed of delivery, or customer service. Which means...
Thousands of small Chinese drug distributors may soon be gobbled up by FCPG and its 13 peers because they simply can’t compete!
In fact, thousands of drug distributors already know they’re doomed because the Chinese Government just placed a...
Country-wide
“Moratorium” on
Internet Drug
Sales Licensing
This moratorium is likely to be in force for several years as the consolidation plan is fully played out.
Can you see why FCPG shares should rocket, and why the company could become America's #1 buyout target?
FCPG literally has a license to steal business from hundreds of competitors. And among the 14 Chinese companies that have this valuable license,” FCPG is the only one that is American-owned!
Yes, the only one (and I’ll show why just ahead).
This fact alone should have you rushing to your online trading account to grab FCPG shares (on the OTCBB exchange). Because...
Nobody else — not any Chinese company, not any American company, not any company anywhere – can now get a license to legally sell drugs over the Internet in China!
The deal is sealed. Just 14 Internet licensees will now dominate an $80 billion drug market. And FCPG is one of them!
Excited? I sure am! But there’s much more to the amazing FCPG story that practically guarantees us 2,800% profit. And to prove it, I need to provide answers to some key questions...
Why did they limit
Internet licensing to just
14 reliable companies?
Two reasons, one of which you already know...
First, to consolidate and modernize China’s archaic drug distribution system, in order to make it highly efficient and eventually on par with the best in the world.
The same thing happened in America back in the ‘60s and ‘70s. Ultimately, 600 American drug distributors consolidated down to just half a dozen big players today.
Here are the top four US companies today...
Advertisement, see disclaimer on bottom
And in just a moment, I’ll show you why it’s practically inevitable that these four companies will get into a bidding war over FCPG, with the final buyout price easily hitting $28 a share.
But first, you need to know that...
The 6,000 Chinese drug distributors mostly comprised two and three unnecessary layers of middlemen that:
That’s one BIG reason for consolidation, but there’s a second reason, and its equally important...
China was recently gripped with a rash of counterfeit drug frauds and illicit Internet drug sales. Yes, I’m talking about fake drugs, but also real prescription drugs sold illegally to consumers over an uncontrolled Internet.
The People’s Republic Of China (PRC) didn’t tolerate that for very long...
And the subsequent brutal crackdown resulted in dozens of perps being jailed, and to be frank these guys may never see the light of day again, if they’re lucky enough to keep their heads, and I mean that literally!
The PRC considers drug fraud among the most serious crimes against its people. And no wonder...
Britain controlled China (and its trade) through opium trafficking from 1787 on, winning the two Opium Wars in 1839 and 1856, and humiliating the Chinese into accepting opium addiction as well as British colonial domination for 156 years.
Make no mistake about the sensitivity – and seriousness — of the drug issue...
The PRC knows full well China can’t become the world’s #1 economic power if its people are addicted to drugs. Nor can it become #1 if its people can’t get authentic and pure prescription meds at a low cost, and in a timely manner.
For these reasons, consolidation has been given a top priority in the government’s $850 billion healthcare overhaul to be completed by 2013.
And they’ve chosen just 14 proven reliable companies to use the Internet business model because it’s a number they feel they can monitor and regulate, not only to ensure drug quality but to prevent fraud and abuse.
Are you beginning to love FCPG? Or more accurately, grasping what owning its shares can do for you because this American company is one of the fortunate fourteen? Let me show you...
Here’s what the Internet business
model can accomplish
Depending on the province and local customs, FCPG’s Internet business model will eliminate at least two — and in some cases three — layers of unnecessary middlemen. And the result may be...
1. Lower prices on drugs for hospitals, clinics, and drugstores by an average of 15%.
2. Higher profit margins for FCPG by 100%!
Imagine what growing 15 times bigger in a year, combined with a doubling of the profit margins, could do for FCPG shares. And if you have any doubts this will happen, just ask yourself...
What Chinese businessman in his right mind would pay 15% or more for the same product? And then get worse service, slower delivery, and no government guarantee of drug purity?
Also consider that Chinese hospitals, health clinics, drug stores, and traditional Chinese medicine shops will now be able to lower prices for their own profits.
Also consider that the fast-growing Chinese middle class are buying more and more American medicines, including popular over the counter remedies like Advil, Prilosec, and Neosporin, to name just a few of the thousands of Western products FCPG will sell!
Remember, the 14 anointed companies must serve 1.5 billion people, so they’ll be expanding very rapidly, especially since the goal of the PRC government is to provide uniform healthcare to all of its citizens, even in rural areas, by 2013!
This story just keeps getting better. Check out FCPG’s brilliant growth strategy...
FCPG’s corporate structure and
business expansion plan
(and how we could score 2,800% profit)
Advertisement, see disclaimer on bottom
Here’s why FCPG’s business could spread like wildfire, why its shares should multiply many times over, and why it could become America’s #1 buyout target, thus setting up our 2,800% profit score!
FCPG is a publicly-traded US-firm based in Nevada. This is a big advantage because you can confidently invest in a US company, rather than take a chance on a Chinese firm. And even moreso in this case because...
FCPG uses a unique corporate structure, the Wholly Owned Foreign Entity (WOFE), which was created specifically to protect Hong Kong capitalists when that island was returned to China by the British in 1997.
The privileged WOFE structure works like this...
A foreign corporation buys a Hong Kong corporation that buys a Chinese company. In this case, FCPG set up a Hong Kong corporation that bought the successful drug distributor in Yunnan Province who then obtained the Internet license. And under the WOFE structure, FCPG enjoys the following major advantages...
1.Freedom to implement the parent company’s worldwide business strategies without the restrictions of Chinese Law.
2.Ability to conduct business in China, invoice in Chinese currency (RMB) and collect receivables in RMB.
3.The right to convert Chinese RMB profits to US dollars and take them out of the country and home to shareholders.
4.Greater protection of intellectual property rights.
For two examples of very successful WOFE corporations that started out small, check out Suntech Power Holdings (STP: NYSE) with a market cap of $1.6 billion. Or Semiconductor Manufacturing International Corp (SMI: NYSE) with a market cap of $1.5 billion.
FCPG could be next in line for spectacular growth, and here’s what ensures we’ll score BIG on the coming buyout!
No other American company is a WOFE that owns all or any part of the other 13 Chinese drug distributors who’ve been granted the Internet sales licenses.
FCPG is the only one. It’s an incredible advantage. In effect, a legal monopoly!
Remember, China is the 3rd largest pharmaceutical market in the world. It’s also the fastest growing drug market in the world. That’s why I say go online to your trading account and act on FCPG now!
Still need to know more. Okay, consider this...
Every big US drug distributor wants a piece of the action, preferably a big piece. But not one can get the Internet license now, and therefore not one can compete in China. Which brings us to the most important point..
The only way US companies can tap into
the Chinese drug market is to buy FCPG.
Yes, here’s the earth-shattering news you’ve been waiting for that practically guarantees us 2,800% profits!
The Big Four — McKesson, Cardinal Health, Amerisource-Bergen, and Owens-Minor – have a problem...
How can they grow? The US market is mature, and while there could be some growth under the new Healthcare Reform Bill, it won’t be fully implemented for 5 years, provided it isn’t repealed first.
Meanwhile, a report on the “US drug distribution” industry, prepared for institutional investors by the prestigious research firm, Gerson-Lehman Group, concluded the US giants have only 3 ways to grow...
Vertical integration, such as buying up cancer clinics and then becoming the sole provider of cancer drugs to those clinics.
Merging with European firms, but they’ll pay dearly for any deal because the European market is also mature.
Getting into the Chinese market, the fastest growing pharmaceutical market in the world, currently #3 but on it’s way to becoming #1.
Advertisement, see disclaimer on bottom
Gerson-Lehman says none of these options will be easy, and the 3rd one will be the most difficult because of the hurdles and hoops US companies must jump over and through in China.
Chinese market near impossible to crack
(but FCPG offers easy entry)
The American Chamber of Commerce recently surveyed 388 large companies doing business in China and released an alarming report — It’s getting harder and harder to do business in China.
China joined the World Trade Organization in 2001, and ever since it’s put on a public face of “welcoming foreign companies” but the reality on the ground is entirely different.
US firms say trading conditions have actually worsened because of 3 things: (1) the Chinese mandate to buy home-grown technologies; (2) highly inconsistent regulatory interpretations; (3) irregular enforcement of laws, province by province.
But the good news for us is that FCPG bypasses all of these problems because of its WOFE status.
The WOFE advantage cannot be underestimated. Look here..
Recently four Rio Tinto executives were jailed on bribery charges (and of course they couldn’t do business without first making those bribes). And you’ll recall Google’s ongoing fight with the PRC over “freedom of Internet” usage in China.
But wait! Can’t one of the BIG FOUR set up its own WOFE and bypass these kinds of problems...
Potentially, yes. It takes about a year and $1 million to get the Hong Kong corporation and WOFE structure in place.
But they’d still have to get one of the remaining 13 Chinese Internet licensees to give up stock and partner with them. And why would any of them do that?
These companies just won the lottery. They’ve been given a license to become DRUG KINGS. To paraphrase an old popular movie – “They don’t need no stinking partners!”
What’s more, China has made their decision on the 14 consolidation winners. Just one is an American-owned WOFE, and it’s highly unlikely they’d allow any others (take my word for it – they won’t).
Next question: FCPG still has to compete with 13 other companies with Internet licenses. Can they still win big? You bet they can!
First, FCPG succeeded in becoming a very profitable, well respected, and fully trusted (by the gov’t) drug distributor, when they competed against all comers on a level playing field.
And now they’ve got the enormous advantage of the Internet license to serve 1.5 billion people. When you consider that 4 major players serve 300 million people in America, you realize there’s plenty of business for 14 big companies in China. Second...
The FCPG Business Strategy includes desirable membership benefits.
To leverage Internet fulfillment and speed its growth, FCPG will offer enticing membership benefits to its customers, as follows:
1.FREE Personal Computer to all customers agreeing to place 70% of their orders with FCPG (at 15% savings). And this computer will have a fast-access link to FCPG’s proprietary customer-service web site.
2.Access to a 30,000 strong product line, including difficult to obtain specialty drugs, which will cover 100% of most client’s needs.
3.More favorable payment terms than competitors can offer.
4.Discount pricing on volume purchases (beyond 15% savings).
5.Store signage indicating FCPG membership, thus ensuring government-backed drug authenticity and purity, as well as branding for future drug-store-chain retail operations (think Walgreen’s or CVS in America).
FCPG is making it really easy for customers to switch, or to expand current purchasing because it can offer 100% of what their customers need — all at 15% lower prices with faster delivery!
Again, no competitor without the Internet license can compete, but how fast can they grow? And...
What’s FCPG’s total market size?
Right now, FCPG is the only Internet licensee serving the 46 million people in Yunnan province. And they’ve been invited into Ningxia province, with 6.2 million people. And their business plan also calls for expansion into the following provinces.
Advertisement, see disclaimer on bottom
That’s a total market of nearly 500 million people! And for the final proof of our 2,800% profit potential, look and see how.
FCPG grows from a $21 million company to a $300 million company in one year, and then gets bought out for $600 million because:
1. FCPG currently has 4,700 customers that fulfill 10% of their needs from the company’s 5,000 item product line. But with the free PC and ease of Internet ordering, plus expansion to 30,000 products, plus a 15% price cut, customers are projected to fulfill 70% of their needs, which is a 7-fold increase in sales to $147 million annually.
2. FCPG also expects to add at least 5,000 new customers the first year, based on the same benefits above. Assuming the same cus- tomer profile (placing 70% of their orders with FCPG), revenues will more than double to $300 million.
3. Finally, $300 million is based solely on business projected in Yunnan and Ningxia provinces (52 million people) and doesn’t count expansion into the other provinces, comprising another 400 million people (although this expansion will come after the first year).
With the Internet business model, FCPG’s profit margins could double!
Now do you see why FCPG will likely be bought out for $600 million, and possibly even more?
I’m convinced McKesson, Cardinal Health, AmerisourceBergen, and Owens-Minor will be fighting over FCPG very soon. They have to, if they want to break into the fastest-growing pharmaceutical market in the world!
Remember, FCPG is the only American company with WOFE privileges that also has the Internet license, making it free of onerous Chinese laws and restrictions. In other words, GAME OVER and FCPG wins!
I’m telling you, if ever there was ever a slam-dunk winner, the American FCPG with its Chinese Internet drug sales license and WOFE privileges is it!
It’s the fastest (maybe the only) way for one of America’s BIG FOUR to get into the fast-growing Chinese drug market, setting up our 2,800% profit score!
Check with your investment advisor, check my facts, do your due diligence. But call your broker or go online and get your FCPG shares today. Any price under $5 is great, but hurry and you can get them at $1 to $1.50 per share.
I say First China Pharma Group could be the most successful investment of the decade, and possibly the biggest score of your investing career!
ACT ON FCPG TODAY!
One last thing... you’ve received this advance information on FCPG because I wanted to demonstrate the extraordinary advantages I bring to my readers each month!
Breakaway Stocks is not about ordinary stocks, but rockets that will shoot up 5, 10, 20, even 30 times higher, all because of unique circumstances and competition-slaying advantages.
You’ve just witnessed the top-drawer research I do for my readers. So, why not join us at Breakaway Stocks on a regular basis? That way, you won’t miss a single fortune-making opportunity in the months to come.
See the next page for my special subscription offers that includes 4 valuable FREE REPORTS with yet more fortune-making opportunities like the one you’ve been reading about today.
Try my letter risk-free. I know you’ll be glad you did. But first, act on FCPG right now!
“My Publisher Thinks I’m Crazy – But I Want To Give You $520 Worth Of My Best Research, Absolutely Free – Then Show You How To
Multiply That Amount 10 Fold!”
Yes, you read that right...
Not only am I giving you $520 worth of my most in-depth profitable research for FREE, but I’m guaranteeing you, it’ll be worth no less than $5,200 within the next 12 months.
Hi, my name is Eric Dickson, editor of Breakaway Stocks, and I’m making you this bold offer not out of blind charity, but because I know once you profit along side me, you’ll become a customer for life...
And from my prospective - that’s just good business.
To give you an example of the type of wealth multiplying profits you’ll have exclusive access to, have a look at what I’ve recently returned current subscribers:
SWHC: $2.61-$5.80 = 122% Gain
DRJ: $0.84-$2.20 = 162% Gain
VMW: $22.10-$89.18 = 303% Gain!!
TXN: $14.77-$28.98 = 96% Gain
SSO: $25.62-$45.70 = 78% Gain
CCIH: $13.90-$30.70 = 121% Gain
WGMGY.PK: $0.013-$0.03 = 131% Gain
BORN: $7.10-$20.50 = 189% Gain
Now to be fair I did have some losers during this period:
ISSI: $12.05-$9.15 = 24% Loss
OPTT: $6.95-$6.71 = 3.5% Loss
STRL: $14.80-$12.72 = 14% Loss
On balance I think you’ll agree the good outweighs the bad.
See, the moment you sign up for your FREE subscription to The Daily Market Beat and Small Cap Fortunes you’ll get expert insights into proven profit producing investment strategies like:
•ADRs – Bank explosive profits from overseas markets – Singapore, Hong Kong, New Delhi, Sao Palo, you’ll be making money in every corner of the globe!
•IPOs – Get into the hottest investments on the market today BEFORE the street finds out tomorrow!
•ETFs – Want lightening fast returns without staring at a trading screen all day? You’ll find them here (we’ve got the countries leading expert to guide you!)
•Penny Stocks – From $0.1 to $0.25, it happens everyday – and it’s good enough to turn $5,000 into $125,000. Sound good? We’ll show you how!
•Small Caps – The fertile proven profit grounds of the Over-The-Counter market. This is where you’ll find a steady stream of triple-digit returns!
•Commodities – Oil, silver, gold, wheat, pork bellies, you name it - you’ll profit from it, regardless of if they go up or down!
•And $Much, $Much $More!
I urge you to take me up on this offer. I can’t promise you’ll ever see it again. Get your first fortune-building issue today!
The profits are mere moments away… Start now!
Staying One Step Ahead
Of The Market Is Easy...
With the Internets most comprehensive newsletter, The Daily Market Beat and Small Cap Fortunes! With information and strategies on the hottest stocks tips and investing techniques... it will change the way to look at making money -
Sincerely,
Eric Dickson
Editor, Breakaway Stocks
IMPORTANT NOTICE AND DISCLAIMER: This featured company sponsored advertising issue of Breakaway Stocks does not purport to provide an analysis of any company’s financial position, operations or prospects and this is not to be construed as a recommendation by Breakaway Stocks or an offer or solicitation to buy or sell any security. First China Pharmaceutical Group, (FCPG), the company featured in this issue, appears as paid advertising, paid by Mediacom Strategies Inc. to provide public awareness for FCPG. Mediacom Strategies Inc. has approved and signed off as “approved for public dissemination” all statements made herein regarding First China Pharmaceutical Group’s history, assets, technologies, current as well as prospective business operations and industry information. Breakaway Stocks and Capital Financial Media (CFM) have used outside research and writers using public information to create the advertisement coming from Breakaway Stocks about FCPG. Although the information contained in this advertisement is believed to be reliable, Breakaway Stocks and CFM makes no warranties as to the accuracy of any of the content herein and accepts no liability for how readers may choose to utilize the content. Readers should perform their own due-diligence, including consulting with a licensed, qualified investment professional or analyst. Further, readers are strongly urged to independently verify all statements made in this advertisement and perform extensive due dili- gence on this or any other advertised company. Breakaway Stocks is not offering securities for sale. An offer to buy or sell can be made only with accompanying disclosure documents and only in the states and provinces for which they are approved. Many states have established rules requiring the approval of a security by a state security administrator. Check with http://www.nasaa.org or call your state security administrator to determine whether a particular security is licensed for sale in your state. Many companies have information filed with state securities regulators and many will supply investors with additional information on request. CFM has received and managed a total production budget of $600,000 for this advertising effort and will retain any amounts over and above the cost of production, copywriting services, mailing and other distribution expenses, as a fee for its services. Breakaway Stocks is paid $3,000 as an editorial fee from CFM and also expects to receive new subscriber revenue as a result of this advertising effort. *More information can be received from First China Pharmaceutical Group’s investor relations firm, or at First China Pharmaceutical Group’s website www.firstchinapharma.com. Further, specific financial information, filings and disclosures as well as general investor information about publicly traded companies like First China Pharmaceutical Group, advice to investors and other investor resources are available at the Securities and Exchange Commission website www.sec.gov and www.nasd.com. Any investment should be made only after consulting with a qualified investment advisor and after reviewing the publicly available financial statements of and other information about the company and verifying that the investment is appropriate and suitable. Investing in securities is highly speculative and carries a great deal of risk especially as to new companies with limited operations and no history of earnings. The information contained herein contains forward-looking information within the meaning of section 27a of the Securities Act of 1993, as amended, and section 21e of the Securities Exchange Act of 1934, as amended, including statements regarding expected growth of the featured company. In accordance with the safe harbor pro- visions of the Private Securities Litigation Reform Act, First China Pharmaceutical Group notes that statements contained herein that look forward in time, which include everything other than historical information, involve risks and uncertainties that may affect the Company’s actual results of operations. Factors that could cause actual results to differ include the size and growth of the market, the Company’s ability to fund its capital requirements in the near term and in the long term; pricing pressures, technology issues etc.
Risk Analysis
Tracking 1051 U.S. listed China Stocks and Counting...
Tracking 1529 U.S. Stocks and Counting...